Literature DB >> 6135162

Alpha 2-adrenoceptors in platelets of spontaneously hypertensive rats.

M Minuth, K H Jakobs.   

Abstract

Alpha 2-adrenoceptors were studied in platelets of stroke-prone spontaneously hypertensive rats (SpSHR) and of normotensive Wistar Kyoto control rats (WKY). In platelets of female SpSHR with established hypertension but not in those of normotensive WKY, specific binding of the alpha 2-adrenoceptor ligand, [3H]yohimbine, was found. Compared with human platelets (KD and B max about 3 nM and 200 fmol/mg protein, respectively), [3H]yohimbine binding to SpSHR platelets was of lower affinity (KD about 20 nM) and of lower capacity (B max about 30 fmol/mg protein). The potency orders of alpha-adrenoceptor agonists (clonidine greater than adrenaline greater than phenylephrine) and antagonists (yohimbine greater than or equal to phentolamine much greater than prazosin) in competing with [3H]yohimbine indicated that the binding sites in SpSHR platelets are of the alpha 2-adrenoceptors type. Similar data were obtained in platelets of 7-9 week old hypertensive rats without established hypertension. Furthermore, adrenaline inhibited SpSHR but not WKY platelet adenylate cyclase. This inhibition, which was smaller than in human platelets, was also found in platelets of 4 week old SpSHR but not in the corresponding control rats. The data show that in SpSHR alpha 2-adrenoceptors can appear, which may play a significant role in the pathogenesis of hypertension.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135162     DOI: 10.1007/bf00512381

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  28 in total

1.  Heterogeneity of radioligand binding to alpha-adrenergic receptors. Analysis of guanine nucleotide regulation of agonist binding in relation to receptor subtypes.

Authors:  B B Hoffman; D Mullikin-Kilpatrick; R J Lefkowitz
Journal:  J Biol Chem       Date:  1980-05-25       Impact factor: 5.157

2.  Characterization of alpha- and beta-adrenergic receptors linked to human platelet adenylate cyclase.

Authors:  K H Jakobs; W Saur; G Schultz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-05       Impact factor: 3.000

3.  The enzymatic preparation of [alpha-(32)P]nucleoside triphosphates, cyclic [32P] AMP, and cyclic [32P] GMP.

Authors:  T F Walseth; R A Johnson
Journal:  Biochim Biophys Acta       Date:  1979-03-28

4.  Is adrenaline the cause of essential hypertension?

Authors:  M J Brown; I Macquin
Journal:  Lancet       Date:  1981-11-14       Impact factor: 79.321

5.  Evidence of an increase in brain postsynaptic alpha 1-receptors in spontaneously hypertensive rats.

Authors:  R Gheyouche; G Le Fur; O Colotte; M C Burgevin; A Uzan
Journal:  J Pharm Pharmacol       Date:  1980-05       Impact factor: 3.765

Review 6.  Cardiovascular regulation by central adrenergic mechanisms and its alteration by hypotensive drugs.

Authors:  G Haeusler
Journal:  Circ Res       Date:  1975-06       Impact factor: 17.367

Review 7.  Alpha-adrenoceptor subclassification.

Authors:  K Starke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1981       Impact factor: 5.545

8.  Central neurotransmitter receptors in hypertensive rats.

Authors:  E H Cantor; S Abraham; S Spector
Journal:  Life Sci       Date:  1981-02-02       Impact factor: 5.037

9.  Alterations in central and peripheral adrenergic receptors in deoxycorticosterone/salt hypertensive rats.

Authors:  S Yamada; H I Yamamura; W R Roeske
Journal:  Life Sci       Date:  1980-12-15       Impact factor: 5.037

10.  Signal transformation involving alpha-adrenoceptors.

Authors:  K H Jakobs; G Schultz
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

View more
  2 in total

Review 1.  Blood platelets in human essential hypertension.

Authors:  F De Clerck
Journal:  Agents Actions       Date:  1986-08

2.  Platelet-vessel wall interactions in hemostasis: implication of 5-hydroxytryptamine.

Authors:  F De Clerck; Y Somers; L Van Gorp
Journal:  Agents Actions       Date:  1984-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.